In Pharma Sustainability, AstraZeneca, Johnson & Johnson Rate High

On a scale of 1 to 100, AstraZeneca and Johnson & Johnson are the only pharmaceutical companies to rate above 70 in a recent survey of sustainability practices in the sector.

At 76 and 75, respectively, AstraZeneca and Johnson & Johnson lead the first-ever review of the pharmaceutical sector by Climate Counts.

Other firms scoring highly are Baxter (66) and GlaxoSmithKline, Pfizer and Schering-Plough, all three of which scored 60.

Climate Counts evaluates firms' commitments in four areas:

• whether they have measured their carbon footprint
• if they reduced their impact on global warming
• if they have supported or blocked climate legislation or policy
• to what level they have publicly disclosed their climate actions

AstraZeneca scored highly in all sectors except for policy, in which it scored a zero out of ten.

Johnson & Johnson scored highly in all sectors except for measuring its own carbon footprint, an area in which it scored 12 out of 22.